| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 812803 | 25 ug | $245 | ||
| 812804 | 100 ug | $595 |
| Application | ELISA, BLI |
|---|---|
| Format | Liquid, Biotinylated |
| Expression Host | CHO |
| Target Name | IL2RA, CD25, p55 |
| Species | Human |
| Sources | Recombinant Human CD25 (Glu22-Cys213) with C-terminus Fc-Avi-tag is expressed in CHO cell. This protein was site-specifically labeled with Biotin by BirA ligase. |
| Accession Number | P01589 |
| Molecular Weight | The protein has a predicted molecular weight of 50.2 kDa. Under DTT-reducing conditions, it migrates at approximately 65 kDa on SDS-PAGE. |
| Affinity Tag | C-Fc-Avi |
| Purity | >95% based on SDS-PAGE under reducing condition |
| Regulatory Status | RUO |
| Formulation | 1xPBS buffer, pH7.4, 0.22 µm filtered |
| Endotoxin level | Not tested |
| Protein Concentration | 25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration. |
| Storage and Handling | Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability. |
CD25 (IL2RA), a type I transmembrane glycoprotein, is expressed on activated T cells, regulatory T cells, and dendritic cells. It binds IL-2 with low affinity on its own, but upon associating with the IL-2 receptor beta (CD122) and common gamma chain (CD132), it forms a high-affinity complex that triggers intracellular signaling pathways like MAPK and JAK/STAT. CD25 is involved in immune regulation and plays a role in autoimmune diseases, including type 1 diabetes. Soluble CD25 (sIL-2Ralpha) is released during immune responses and is a marker for tumor burden in hematological malignancies, including leukemias and lymphomas, as well as some solid tumors like melanoma and carcinomas. The presence of sIL-2Ralpha in circulation reflects tumor activity and is associated with immune modulation in cancer progression.
